Umbralisib
- Generic Name
- Umbralisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H24F3N5O3
- CAS Number
- 1532533-67-7
- Unique Ingredient Identifier
- 38073MQB2A
- Background
Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are r...
- Indication
Umbralisib does not have any approved therapeutic indications.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02535286
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath